Creating functional small-diameter tissue-engineered blood vessels has not been successful to date. Moreover, the processes underlying the in vivo remodeling of these grafts and the fate of cells seeded onto scaffolds remain unclear. Here we addressed these unmet scientific needs by using intravital molecular imaging to monitor the development of tissue-engineered vascular grafts (TEVG) implanted in mouse carotid artery.
Methods and Results:
Green fluorescent protein–labeled human bone marrow–derived mesenchymal stem cells and cord blood–derived endothelial progenitor cells were seeded on polyglycolic acid–poly-L-lactic acid scaffolds to construct small-caliber TEVG that were subsequently implanted in the carotid artery position of nude mice (n = 9). Mice were injected with near-infrared agents and imaged using intravital fluorescence microscope at 0, 7, and 35 days to validate in vivo the TEVG remodeling capability (Prosense680; VisEn, Woburn, MA) and patency (Angiosense750; VisEn). Imaging coregistered strong proteolytic activity and blood flow through anastomoses at both 7 and 35 days postimplantation. In addition, image analyses showed green fluorescent protein signal produced from mesenchymal stem cell up to 35 days postimplantation. Comprehensive correlative histopathological analyses corroborated intravital imaging findings.
Conclusions:
Multispectral imaging offers simultaneous characterization of in vivo remodeling enzyme activity, functionality, and cell fate of viable small-caliber TEVG.
Get full access to this article
View all access options for this article.
References
1.
DeFrancesC.J., LucasC.A., BuieV.C., GolosinskiyA.2006. National Hospital Discharge Survey. Natl Health Stat Report, 2008,5:1–20.
2.
DearaniJ.A., DanielsonG.K., PugaF.J., SchaffH.V., WarnesC.W., DriscollD.J., SchleckC.D., IlstrupD.M.Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac Surg, 75:399–410. 2003discussion 410–391.
3.
L'HeureuxN., McAllisterT.N., de la FuenteL.M.Tissue-engineered blood vessel for adult arterial revascularization. N Engl J Med, 357:1451. 2007.
Shin'okaT., MatsumuraG., HibinoN., NaitoY., WatanabeM., KonumaT., SakamotoT., NagatsuM., KurosawaH.Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg, 129:1330. 2005.
6.
RohJ.D., BrennanM.P., Lopez-SolerR.I., FongP.M., GoyalA., DardikA., BreuerC.K.Construction of an autologous tissue-engineered venous conduit from bone marrow-derived vascular cells: optimization of cell harvest and seeding techniques. J Pediatr Surg, 42:198. 2007.
7.
KaushalS., AmielG.E., GuleserianK.J., ShapiraO.M., PerryT., SutherlandF.W., RabkinE., MoranA.M., SchoenF.J., AtalaA., SokerS., BischoffJ., MayerJ.E.Jr.Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med, 7:1035. 2001.
SchmidtD., AsmisL.M., OdermattB., KelmJ., BreymannC., GossiM., GenoniM., ZundG., HoerstrupS.P.Engineered living blood vessels: functional endothelia generated from human umbilical cord-derived progenitors. Ann Thorac Surg, 82:1465–1471. 2006discussion 1471.
10.
MirenskyT.L., BreuerC.K.The development of tissue-engineered grafts for reconstructive cardiothoracic surgical applications. Pediatr Res, 63:559. 2008.
11.
NelsonG.N., MirenskyT., BrennanM.P., RohJ.D., YiT., WangY., BreuerC.K.Functional small-diameter human tissue-engineered arterial grafts in an immunodeficient mouse model: preliminary findings. Arch Surg, 143:488. 2008.
12.
Shin'okaT., ImaiY., IkadaY.Transplantation of a tissue-engineered pulmonary artery. N Engl J Med, 344:532. 2001.
13.
JafferF.A., LibbyP., WeisslederR.Molecular imaging of cardiovascular disease. Circulation, 116:1052. 2007.
14.
SosnovikD.E., NahrendorfM., WeisslederR.Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol, 103:122. 2008.
15.
AikawaE., NahrendorfM., SosnovikD., LokV.M., JafferF.A., AikawaM., WeisslederR.Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation, 115:377. 2007.
SodianR., HoerstrupS.P., SperlingJ.S., DaebritzS., MartinD.P., MoranA.M., KimB.S., SchoenF.J., VacantiJ.P., MayerJ.E.Jr.Early in vivo experience with tissue-engineered trileaflet heart valves. Circulation, 102,19 Suppl 3:III22. 2000.
22.
GoyalA., WangY., SuH., DobruckiL.W., BrennanM., FongP., DardikA., TellidesG., SinusasA., PoberJ.S., SaltzmanW.M., BreuerC.K.Development of a model system for preliminary evaluation of tissue-engineered vascular conduits. J Pediatr Surg, 41:787. 2006.
23.
RohJ.D., NelsonG.N., BrennanM.P., MirenskyT.L., YiT., HazlettT.F., TellidesG., SinusasA.J., PoberJ.S., SaltzmanW.M., KyriakidesT.R., BreuerC.K.Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. Biomaterials, 29:1454. 2008.
24.
Lopez-SolerR.I., BrennanM.P., GoyalA., WangY., FongP., TellidesG., SinusasA., DardikA., BreuerC.Development of a mouse model for evaluation of small diameter vascular grafts. J Surg Res, 139:1. 2007.
25.
NelsonG.N., RohJ.D., MirenskyT.L., WangY., YiT., TellidesG., PoberJ.S., ShkarinP., ShapiroE.M., SaltzmanW.M., PapademetrisX., FahmyT.M., BreuerCK.Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo. FASEB J, 22:3888. 2008.
26.
Melero-MartinJ.M., De ObaldiaM.E., KangS.Y., KhanZ.A., YuanL., OettgenP., BischoffJ.Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res, 103:194. 2008.
27.
PittengerM.F., MackayA.M., BeckS.C., JaiswalR.K., DouglasR., MoscaJ.D., MoormanM.A., SimonettiD.W., CraigS., MarshakD.R.Multilineage potential of adult human mesenchymal stem cells. Science, 284:143. 1999.
28.
KitamuraT., OnishiM., KinoshitaS., ShibuyaA., MiyajimaA., NolanG.P.Efficient screening of retroviral cDNA expression libraries. Proc Natl Acad Sci USA, 92:9146. 1995.
29.
Melero-MartinJ.M., KhanZ.A., PicardA., WuX., ParuchuriS., BischoffJ.In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood, 109:4761. 2007.
HattoriH., HiguchiK., NogamiY., AmanoY., IshiharaM., TakaseB.A novel real-time fluorescent optical imaging system in mouse heart: a powerful tool for studying coronary circulation and cardiac function. Circulation, 2:277. 2009.
32.
AikawaE., NahrendorfM., FigueiredomJ.L., SwirskiF.K., ShtatlandT., KohlerR.H., JafferF.A., AikawaM., WeisslederR.Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation, 116:2841. 2007.
33.
ChoS.W., KimI.K., KangJ.M., SongK.W., KimH.S., ParkC.H., YooK.J., KimB.S.Evidence for in vivo growth potential and vascular remodeling of tissue-engineered artery. Tissue Eng, 15:901. 2009.
Shin'okaT.[Clinical results of tissue-engineered vascular autografts seeded with autologous bone marrow cells]Nippon Geka Gakkai Zasshi, 105:459. 2004.
37.
KimY.S., GalisZ.S., RachevA., HanH.C., VitoR.P.Matrix metalloproteinase-2 and -9 are associated with high stresses predicted using a nonlinear heterogeneous model of arteries. J Biomech Eng, 131:011009. 2009.
GalisZ.S., KhatriJ.J.Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res, 90:251. 2002.
42.
AthanasiouK.A., NiederauerG.G., AgrawalC.M.Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials, 17:93. 1996.
43.
HjortnaesJ., BoutenC.V., Van HerwerdenL.A., GrundemanP.F., KluinJ.Translating autologous heart valve tissue engineering from bench to bed. Tissue Eng Part B Rev, 15:307. 2009.
